Who
Jeffrey S. Farrow
Director
Company insider
Files Form 4 as: Director, Achieve Life Sciences; Officer, Tarsus Pharmaceuticals; Chief Financial Officer, Global Blood Therapeutics; Chief Financial Officer, ZS Pharma; CFO, Hyperion Therapeutics; V.P., Finance and CAO, Renovis.
In numbers
- Trades disclosed
- 200
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $7.9M
- Companies
- 6
- Companies where not an officer
- 1
- First trade
- 1 Jul 2007
- Last trade
- 27 Jul 2026
- Last filed
- 29 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Jul 2026filed 29 Jul 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 27 Jul 2026filed 29 Jul 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,700 at $0.00 | filing |
| 27 Jul 2026filed 29 Jul 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 27 Jul 2026filed 29 Jul 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,700 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $877K14,396 at $60.95 | filing |
| 16 Jun 2026filed 17 Jun 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $877K14,396 at $60.95 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —27,881 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,881 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,881 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —27,881 | filing |
| 29 May 2026filed 2 Jun 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —47,250 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —47,250 at $0.00 | filing |
| 19 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $146K2,186 at $67.00 | filing |
| 19 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $146K2,186 at $67.00 | filing |
| 18 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $147K2,133 at $68.71 | filing |
| 18 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $147K2,133 at $68.71 | filing |
| 17 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $147K2,111 at $69.42 | filing |
| 17 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $147K2,111 at $69.42 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —13,042 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,020 at $0.00 | filing |
News
Reviewing Tarsus Pharmaceuticals (NASDAQ:TARS) and Novo Nordisk A/S (NYSE:NVO)TARS · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Jeffrey S. Farrow; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.